Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

IJID Regions is a pioneering open access journal published by Elsevier, focusing on the critical fields of epidemiology, infectious diseases, and public health. Established in 2021, the journal aims to provide a platform for disseminating high-quality, innovative research that addresses pressing health issues and informs evidence-based practices in communities around the globe. With its impact factors reflecting a Tier Q2 and Q3 ranking in various medical subcategories on the Scopus platform, IJID Regions is positioned as a valuable resource for researchers, health professionals, and policy-makers striving to enhance public health outcomes. This journal not only champions open access since its inception, promoting the free flow of information, but also welcomes contributions that shed light on contemporary challenges in environmental and occupational health. Its commitment to fostering dialogue and collaboration in the health sciences is paramount, making it an essential read for those engaged in advancing public health knowledge and initiatives.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Diseases is a premier Open Access journal dedicated to the dissemination of cutting-edge research in the field of medicine, particularly focusing on the multifaceted challenges posed by various diseases. Published by MDPI in Switzerland since 2013, this journal provides a platform for innovative studies and comprehensive reviews that address the latest developments in disease prevention, diagnosis, and treatment. With an E-ISSN of 2079-9721, it holds a respectable rank of #394 out of 636 in the General Medicine category according to Scopus, indicating a growing impact within the community, marked by its 38th percentile ranking. The journal, covering converged years from 2020 to 2024, aims to foster interdisciplinary collaboration and knowledge sharing among researchers, healthcare professionals, and students, ultimately contributing to the enhancement of global health outcomes. Accessible without charge, Diseases exemplifies a commitment to advancing research and practices aimed at improving human health on a global scale.

JMIR Public Health and Surveillance is a premier open access journal that has been at the forefront of public health research since its inception in 2015. Published by JMIR PUBLICATIONS, INC in Canada, this journal holds an impressive Q1 ranking in both Health Informatics and Public Health, Environmental and Occupational Health as of 2023. With a commendable Scopus Rank of #18 out of 665 in Public Health and #10 out of 138 in Health Informatics, JMIR Public Health and Surveillance stands out for its rigorous peer-reviewed articles that contribute significantly to the advancement of knowledge in these vital fields. The journal is committed to promoting research that advances the understanding and surveillance of health trends, disease outbreaks, and population health metrics, thus serving as an invaluable resource for researchers, professionals, and students alike. By facilitating open access to high-quality content, it ensures that results of critical public health research are readily available, ultimately helping to inform policy and public health initiatives across the globe.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

Gut Pathogens, published by BMC in the United Kingdom, is a premier open-access journal focusing on the intersection of gut health and infectious diseases. With its impact firmly established since its inception in 2009, the journal has earned impressive rankings, including Q1 in renowned categories such as Gastroenterology, Infectious Diseases, Microbiology, and Parasitology, while maintaining a strong presence in Virology. The journal serves as a vital resource for researchers, professionals, and students interested in the intricate relationships between gut microbiota and pathogenic organisms, offering insights that drive advancements in treatment and prevention strategies. By providing unrestricted access to high-quality research, Gut Pathogens fosters a collaborative environment, encouraging the dissemination of knowledge and innovation within the field. The journal publishes original research, reviews, and case studies, all designed to address contemporary challenges in gut health, ultimately aiming to improve patient outcomes and public health worldwide.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

Revista Chilena de Infectologia is an esteemed academic journal dedicated to the field of infectious diseases and public health. Published by the SOC CHILENA INFECTOLOGIA, this journal has been pivotal in disseminating crucial research findings since its inception in 2000. While operating under ISSN 0716-1018 and E-ISSN 0717-6341, it aims to contribute to the understanding of both local and global health issues, particularly within the context of Chile. Currently, it holds a Q4 ranking in both the Infectious Diseases and Public Health, Environmental and Occupational Health categories as of 2023, reflecting its unique position among emerging voices in the field. The journal aspires to foster collaboration among researchers, professionals, and students by offering a platform for innovative studies and discussions that address pressing health challenges. Although it is not an Open Access journal, access options through institutional subscriptions are encouraged for a comprehensive review of its significant contributions to infectious disease research.